Save 20% on All Global Market Reports With Code ONLINE20 – Gain Insights Into Tariffs, Inflation, and Industry Trends
What Is the Current Market Size and Growth Rate of the Oral Mucositis Treatment Market?
The oral mucositis treatment market size has grown strongly in recent years. It will grow from $1.95 billion in 2024 to $2.14 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing prevalence of cancer therapies, rise in chemotherapy and radiation treatments, growing awareness of oral health complications, increase in demand for targeted therapies, and rising adoption of preventive and therapeutic treatments.
The oral mucositis treatment market size is expected to see strong growth in the next few years. It will grow to $3.13 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing focus on personalized medicine, rise in number of cancer patients, growing investment in innovative drug development, increasing healthcare expenditure in emerging markets, and rise in regulatory approvals for novel therapies. Major trends in the forecast period include advancement in biologics for oral mucositis, innovation in combination therapies for better efficacy, development of non-invasive treatment options, advanced research in immunotherapy for mucositis, and innovation in personalized treatment regimens.
Claim your free report sample now:
What Are the Key Drivers of the Oral Mucositis Treatment Market?
The increasing use of chemotherapy is expected to propel the growth of the oral mucositis treatment market going forward. Chemotherapy is a medical treatment that uses powerful chemicals to kill or inhibit the growth of cancer cells. The rise in the use of chemotherapy is driven by its effectiveness in targeting cancer cells, offering patients a higher chance of remission and improved survival rates. Oral mucositis treatment helps relieve pain, promote healing, and prevent complications caused by chemotherapy, improving patient comfort during treatment. For example, in May 2022, according to the National Library Of Medicine, a US-based government agency, the annual number of patients needing first-line chemotherapy is projected to rise from 9.8 million in 2022 to 15.0 million by 2040. Therefore, the increasing use of chemotherapy is driving the growth of the oral mucositis treatment market.
How Is the Oral Mucositis Treatment Market Segmented?
The oral mucositis treatment market covered in this report is segmented –
1) By Treatment Type: Pharmaceutical Drugs, Laser Therapy, Cryotherapy, Oral Rinses And Mouthwashes, Other Treatment Types
2) By Route Of Administration: Oral, Intravenous, Subcutaneous, Topical, Other Routes Of Administration
3) By Indication: Chemotherapy-induced Oral Mucositis, Radiotherapy-induced Oral Mucositis, Other Indications
4) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Hospital Pharmacies, Direct Sales
5) By End-User: Hospitals, Homecare Settings, Ambulatory Surgical Centers, Long-term Care Facilities
Subsegments:
1) By Pharmaceutical Drugs: Prescription Drugs, Over-the-counter (OTC) Drugs, Biologics, Small Molecule Drugs
2) By Laser Therapy: Low-Level Laser Therapy (LLLT), High-Level Laser Therapy (HLLT)
3) By Cryotherapy: Ice Chips, Cryotherapy Devices
4) By Oral Rinses and Mouthwashes: Antiseptic Rinses, Antifungal Rinses, Antiviral Rinses, Natural Or Herbal Rinses
5) By Other Treatment Types: Nutritional Supplements, Topical Gels and Ointments, Stem Cell Therapy, Acupuncture
What Are the Key Trends Shaping the Oral Mucositis Treatment Market?
Major companies operating in the oral mucositis treatment market are focusing on developing advanced quick pain relief products to improve patient comfort, enhance treatment adherence, and support better recovery outcomes. Quick pain relief products refer to the ability of a treatment to rapidly reduce pain and maintain relief over time without causing a sharp, burning, or irritating sensation when applied. For instance, in October 2024, Jaguar Health, a US-based company, launched Gelclair, an FDA-approved oral mucositis prescription product for the management and relief of oral mucositis pain. This innovative oral mucositis treatment features a protective gel action and soothing application, helping relieve pain and support oral function in cancer patients. Gelclair is highly effective, providing rapid pain relief and mucosal protection, making it an ideal treatment for oral mucositis in cancer patients by enhancing comfort and supporting oral function during therapy.
Which Are the Top Companies in the Oral Mucositis Treatment Market?
Major companies operating in the oral mucositis treatment market are Sanofi S.A., Amgen Inc., Colgate-Palmolive Company, Aspen Pharmacare Holdings Limited, Swedish Orphan Biovitrum AB (Sobi), Sunstar Group, Norgine B.V., Alliance Pharma plc, Camurus AB, EUSA Pharma, Galera Therapeutics Inc., Enzychem Lifesciences Corporation, CANbridge Pharmaceuticals Inc., Jaguar Health Inc., Monopar Therapeutics Inc., EpicentRx Inc., Innovation Pharmaceuticals Inc., Oragenics Inc., Soleva Pharma LLC, Soligenix Inc.
Get the full oral mucositis treatment market report here:
Which Region Is Projected to Account for the Largest Share of the Oral Mucositis Treatment Market?
North America was the largest region in the oral mucositis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral mucositis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment